# The Longevity Fund

The Longevity Fund is a Venture Capital based in San Francisco, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 2011
- **Assets under management:** Undisclosed
- **Website:** longevity.vc
- **LinkedIn:** https://www.linkedin.com/company/the-longevity-fund

## Regulatory record

- **Reports private funds:** No

## About

The Longevity Fund focuses on investments in therapeutics targeting aging damage. The fund has made 24 investments, including a Seed VC in Behavidence on March 11, 2022. Portfolio exits include Decibel Therapeutics, which exited on February 12, 2021.

## Sectors

- Digital Health
- Biotechnology
- AI/ML

## People

- Laura Deming — Founder and General Partner

## Questions

### Who makes the investment decisions at The Longevity Fund?

Laura Deming, the founder and General Partner, leads all investment decisions. Deming has been singularly focused on the biology of aging since her teenage years, working in Cynthia Kenyon's lab and attending the Thiel Fellowship before launching the firm at 18. She combines scientific evaluation with a long-duration capital approach that reflects her personal conviction in longevity science.

### Is The Longevity Fund structured as a traditional venture firm or something different?

It is a traditional venture capital firm with a concentrated, thesis-specific mandate. The Longevity Fund makes early-stage equity investments in private biotech companies, using standard fund structures. Its operational model is lean, built around Deming's general partnership and a scientific advisory network rather than a large investment team.

### Does The Longevity Fund invest outside the United States?

The firm's known portfolio companies are based in the United States, and its primary investment geography is North America. Deming has evaluated global longevity opportunities through her broader scientific network, but no international portfolio companies have been publicly disclosed.

### What investment stages does The Longevity Fund typically target?

The firm targets seed and Series A rounds, with a focus on platform biotechnology companies that require extended development timelines. Deming has stated publicly that aging science demands capital patience measured in decades, which shapes the fund's preference for early entry at valuations where long holding periods are structurally feasible.

### Which sectors does The Longevity Fund explicitly avoid?

The firm explicitly avoids general healthcare, late-stage biotech, and companies targeting individual age-related diseases without engaging the underlying biology of aging. Its mandate excludes digital health apps, healthcare services, and therapeutic approaches that do not address what Deming defines as the core mechanisms of the aging process.

## Related profiles

- [The London Fund](https://altss.com/profile/the-london-fund)
- [The Longreach Group](https://altss.com/profile/the-longreach-group)

---

Last updated: 2026-07-08T23:36:47.755Z

Canonical page: https://altss.com/profile/the-longevity-fund

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology